Eastman Chemical Company
NYSE:EMNChemicals
-$1.16 today
- Market cap
- $7.13B
- Beta
- 1.07
- P/E (TTM)
- 20.6
- EPS (TTM)
- $3.50
- Dividend yield
- 4.65%
Volume 1.38M
Average 1.33M
EMN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Eastman Chemical CompanyNYSE: EMN
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $65M fell 3.0% year over year, ahead of the -7.2% change in trailing-twelve-month research & development. Sequentially, it rose 8.3% from the prior quarter. Over 3 fiscal years it compounded at -1.1% a year.
Context
- Research & development amounted to 2.9% of revenue in FY2025, up 0.2 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -3.0% holds above the trailing-twelve-month pace of -7.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 255M USD
- Year-over-year change
- +2.0%
- 4-year CAGR
- +0.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 255M | +2.0% |
| FY2024 | 2024-12-31 | 250M | +4.6% |
| FY2023 | 2023-12-31 | 239M | -9.5% |
| FY2022 | 2022-12-31 | 264M | +3.9% |
| FY2021 | 2021-12-31 | 254M | — |
Research & Development vs competitors
How EMN compares with its peers on the latest reported figures
- EMN's LTM Jun 2026 research & development of $246M is the 2nd highest of the 11 companies compared; the peer median is $55M.
- Its year-over-year change of -7.2% is the 7th highest of 10, against a peer median of -4.1%.
- Research & development amounts to 2.8% of revenue for EMN, versus a peer median of 1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $741M | -5.1% | -4.1% | 1.7% | |
| LTM Jun 2026 | $246M | -7.2% | -1.1% | 2.8% | |
| LTM Mar 2026 | $117M | -4.1% | -1.4% | 2.1% | |
| LTM Sep 2026 | $80M | +23.8% | +11.5% | 2.3% | |
| LTM Mar 2026 | $59.62M | +6.3% | -3.8% | 2.5% | |
| LTM Jun 2026 | $55M | -9.8% | +2.4% | 1.5% | |
| LTM Jun 2026 | $55M | +3.8% | -0.6% | 3.0% | |
| LTM Jun 2026 | $52.1M | +4.0% | +9.6% | 2.8% | |
| LTM Sep 2026 | $20.2M | -32.2% | -2.1% | 1.8% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding EMN) | $55M | -4.1% | -1.0% | 1.9% | |
Competitors are the stored peer set for EMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.48B | 10.54B | 9.2B | 9.38B | 8.75B |
| Cost of Revenue | 7.97B | 8.48B | 7.14B | 7.09B | 6.91B |
| Gross Profit | 2.52B | 2.06B | 2.06B | 2.29B | 1.84B |
| Gross Margin | 24.0% | 19.5% | 22.4% | 24.4% | 21.1% |
| Research & Development | 254M | 264M | 239M | 250M | 255M |
| Selling, General & Admin | 795M | 708M | 727M | 664M | 658M |
| Operating Expenses | 1.05B | 972M | 966M | 914M | 913M |
| Depreciation & Amortization | 538M | 477M | 498M | 509M | 513M |
| EBITDA | 1.81B | 1.64B | 1.81B | 1.8B | 1.29B |
| EBITDA Margin | 17.3% | 15.5% | 19.6% | 19.2% | 14.7% |
| Operating Income | 1.47B | 1.08B | 1.1B | 1.38B | 931M |
| Operating Margin | 14.0% | 10.3% | 11.9% | 14.7% | 10.6% |
| Interest Income | 3M | 6M | 10M | 16M | 0 |
| Interest Expense | 192M | 188M | 225M | 216M | 208M |
| Other Income / Expenses | (387M) | (107M) | (9M) | (298M) | (363M) |
| Income Before Tax | 1.08B | 977M | 1.09B | 1.08B | 568M |
| Pre-Tax Margin | 10.3% | 9.3% | 11.8% | 11.5% | 6.5% |
| Income Tax Expense | 215M | 181M | 191M | 170M | 93M |
| Net Income | 857M | 793M | 894M | 905M | 474M |
| Net Margin | 8.2% | 7.5% | 9.7% | 9.6% | 5.4% |
| EPS (Basic) | 6.35 | 6.42 | 7.54 | 7.75 | 4.13 |
| EPS (Diluted) | 6.25 | 6.35 | 7.49 | 7.67 | 4.10 |
| Weighted Avg Shares | 134.9M | 123.5M | 118.6M | 116.7M | 114.7M |
| Weighted Avg Shares (Diluted) | 137.1M | 124.9M | 119.4M | 117.9M | 115.6M |
Eastman Chemical Company
NYSE:EMN
Intrinsic Alpha fair value
Locked
Current Price
$62.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.